Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells

Cancer Biology and Therapy

Volumn 12, Issue 10, 2011, Pages 924-938

  Martinez Outschoorn, Ubaldo E ^a,b   Goldberg, Allison ^a,b   Lin, Zhao ^a   Ko, Ying Hui ^a   Flomenberg, Neal ^a,b   Wang, Chenguang ^a   Pavlides, Stephanos ^a   Pestell, Richard G ^a   Howell, Anthony ^c   Sotgia, Federica ^a,c   Lisanti, Michael P ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aerobic glycolysis; Cancer associated fibroblasts; Drug resistance; Glucose uptake; Metformin; Microenvironment; Mitochondrial oxidative phosphorylation; Oxidative stress; Reactive oxygen species (ROS); Tamoxifen; TIGAR; Tumor stroma; Warburg effect

Indexed keywords

ANTIESTROGEN; ARSENIC TRIOXIDE; DOXORUBICIN; FULVESTRANT; GLUCOSE; KETONE BODY; LACTIC ACID; METFORMIN; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TAMOXIFEN; TP53 INDUCED GLYCOLYSIS AND APOPTOSIS REGULATOR; UNCLASSIFIED DRUG; VELIPARIB;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL ACTIVITY; CELL PROTECTION; CELL STRAIN MCF 7; COCULTURE; CONTROLLED STUDY; FIBROBLAST; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT;

APOPTOSIS; ARSENICALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; FIBROBLASTS; HUMANS; HYPOGLYCEMIC AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KETONE BODIES; LACTIC ACID; METFORMIN; MITOCHONDRIA; OXIDES; POLY(ADP-RIBOSE) POLYMERASES; TAMOXIFEN; TUMOR MICROENVIRONMENT;

EID: 81555210940     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.10.17780     Document Type: Article

References (84)

1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer.LancetOncol 2001; 2:924-938;PMID:11902563; http://dx.doi.org/10.1016/S1470-2045(00)00254-0
2. Lacey JV, Jr., Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39:82-8; PMID:11921173; http://dx.doi.org/10.1002/em.10062
3. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21:28-34; PMID:12506166; http://dx.doi.org/10.1200/JCO.2003.03.088
4. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breastcancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670-4; PMID:17442911; http://dx.doi.org/10.1056/NEJMsr070105
5. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43; PMID:19701242; http://dx.doi.org/10.1038/nrc2713
6. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11:1135-41; PMID:21087898; http://dx.doi.org/10.1016/S1470-2045(10)70257-6
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717; PMID:15894097; http://dx.doi.org/10.1016/S0140-6736(05)66544-0
8. Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J Natl Compr Canc Netw 2009; 7:203-13; PMID:19200418
9. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032-44; PMID:12586780; http://dx.doi.org/10.1210/en. 2002-220620
10. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008; 29:217-33; PMID:18216219; http://dx.doi.org/10.1210/er.2006-0045
11. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008; 68:826-33; PMID:18245484; http://dx.doi.org/10.1158/0008-5472.CAN-07- 2707
12. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004; 10:346S-54S; PMID:14734490; http://dx.doi.org/10.1158/1078-0432.CCR- 031206
13. Dorssers LC, van Agthoven T, Dekker A, van Agthoven TL, Kok EM. Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. Mol Endocrinol 1993; 7:870-8; PMID:8413311; http://dx.doi.org/10.1210/me.7.7.870
14. Brinkman A, de Jong D, Tuinman S, Azaouagh N, van Agthoven T, Dorssers LC. The substrate domain of BCAR1 is essential for anti-estrogen-resistant proliferation of human breast cancer cells. Breast Cancer Res Treat 2010; 120:401-8; PMID:19412734; http://dx.doi.org/10.1007/s10549-009-0403-4
15. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006; 97:263-74; PMID:16333527; http://dx.doi.org/10.1007/s10549-005-9120-9
16. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95:353-61; PMID:12618500; http://dx.doi.org/10.1093/jnci/95.5.353
17. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, et al. Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 2008; 456:663-6; PMID: 19005469; http://dx.doi.org/10.1038/ nature07483
18. Zhou Y, Yau C, Gray JW, Chew K, Dairkee SH, Moore DH, et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7:59; PMID:17407600; http://dx.doi.org/10.1186/ 1471-2407-7-59
19. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23:2469-76; PMID:15753463; http://dx.doi.org/10.1200/JCO.2005.01.172
20. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010; 120:2406-13; PMID: 20530877; http://dx.doi.org/10.1172/JCI41680
21. Nehra R, Riggins RB, Shajahan AN, Zwart A, Crawford AC, Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J 2010; 24:2040-55; PMID:20154269; http://dx.doi.org/10.1096/fj.09-138305
22. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol 2007; 82:85-90; PMID: 17046747; http://dx.doi.org/10.1016/j.yexmp.2006.09.001
23. Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 1998; 18:4499-508; PMID: 9671459
24. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, Landberg G. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004; 90:1942-8; PMID:15138475; http://dx.doi.org/10.1038/sj.bjc.6601831
25. Dhillon NK, Mudryj M. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 2002; 21:4626-34; PMID:12096339; http://dx.doi.org/10.1038/sj.onc.1205576
26. Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, et al. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifentreated breast cancer cells. Cancer Res 2003; 63:4322-6; PMID:12907598
27. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000; 97:9042-6; PMID: 10908655; http://dx.doi.org/10.1073/pnas.160016897
28. Shi L, Dong B, Li Z, Lu Y, Ouyang T, Li J, et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J Clin Oncol 2009; 27:3423-9; PMID:19487384; http://dx.doi.org/10.1200/JCO.2008.17.2254
29. Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9:576-86; PMID:19629072; http://dx.doi.org/10.1038/nrc2683
30. Nazarewicz RR, Zenebe WJ, Parihar A, Larson SK, Alidema E, Choi J, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67:1282-90; PMID:17283165; http://dx.doi.org/10.1158/0008-5472.CAN-06-3099
31. Schiff R, Reddy P, Ahotupa M, Coronado-Heinsohn E, Grim M, Hilsenbeck SG, et al. Oxidative stress and AP- 1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst 2000; 92:1926-34; PMID:11106684; http://dx.doi.org/10.1093/jnci/92.23.1926
32. Seth P, Krop I, Porter D, Polyak K. Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene 2002; 21:836-43; PMID:11850811; http://dx.doi.org/10.1038/sj.onc.1205113
33. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 2009; 16:413-24; PMID:19878873; http://dx.doi.org/10.1016/j.ccr.2009.09.029
34. Woodward TL, Mienaltowski AS, Modi RR, Bennett JM, Haslam SZ. Fibronectin and the alpha(5)beta(1) integrin are under developmental and ovarian steroid regulation in the normal mouse mammary gland. Endocrinology 2001; 142:3214-22; PMID:11416044; http://dx.doi.org/10.1210/en.142.7.3214
35. Schedin P, Mitrenga T, McDaniel S, Kaeck M. Mammary ECM composition and function are altered by reproductive state. Mol Carcinog 2004; 41:207-20; PMID:15468292; http://dx.doi.org/10.1002/mc.20058
36. Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr J 2009; 56:1-7; PMID:18497452; http://dx.doi.org/10. 1507/endocrj.K08E-099
37. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, et al. Carcinomaassociated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123:2518-31; PMID:18767044; http://dx.doi.org/10.1002/ ijc.23802
38. Shekhar MP, Santner S, Carolin KA, Tait L. Direct involvement of breast tumor fibroblasts in the modulation of tamoxifen sensitivity. Am J Pathol 2007; 170:1546-60; PMID:17456761; http://dx.doi.org/10.2353/ajpath.2007.061004
39. Witkiewicz AK, Casimiro MC, Dasgupta A, Mercier I, Wang C, Bonuccelli G, et al. Towards a new "stromalbased"classification system for human breast cancer prognosis and therapy. Cell Cycle 2009; 8:1654-8; PMID:19448435; http://dx.doi.org/10.4161/cc.8.11.8544
40. Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174:2035-43; PMID:19411449; http://dx.doi.org/10.2353/ajpath.2009. 080924
41. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023-34; PMID:19411448; http://dx.doi.org/10.2353/ajpath.2009.080873
42. Martinez-Outschoorn UE, Pavlides S, Whitaker- Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9:2423-33; PMID: 20562526; http://dx.doi.org/10.4161/cc.9.12.12048
43. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumorstroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9:3256-76; PMID:20814239; http://dx.doi.org/10.4161/cc.9.16.12553
44. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFkappaB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515-33; PMID: 20855962; http://dx.doi.org/10.4161/cc.9.17.12928
45. Pavlides S, Tsirigos A, Migneco G,Whitaker-Menezes D, Chiavarina B, Flomenberg N, et al. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle 2010; 9:3485-505; PMID:20861672; http://dx.doi.org/10.4161/cc.9.17.12721
46. Rabinowitz JD, White E. Autophagy and metabolism. Science 2010; 330:1344-8; PMID:21127245; http://dx.doi.org/10.1126/science.1193497
47. Finn PF, Dice JF. Ketone bodies stimulate chaperone-mediated autophagy. J Biol Chem 2005; 280:25864- 70; PMID:15883160; http://dx.doi.org/10.1074/jbc. M502456200
48. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10:1772-83; PMID:21558814; http://dx.doi.org/10.4161/cc.10.11.15659
49. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010; 11:554-65; PMID:20519126; http://dx.doi.org/ 10.1016/j.cmet.2010.04.001
50. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223-8; PMID:10617608; http://dx.doi.org/10.1074/jbc.275.1.223
51. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9:563-75; PMID:19629071; http://dx.doi.org/10.1038/nrc2676
52. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91-9; PMID:15261145; http://dx.doi.org/10.1016/j.ccr.2004.06.007
53. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101:3329-35; PMID: 14985505; http://dx.doi.org/10.1073/pnas.0308061100
54. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269-73; PMID:17062558; http://dx.doi.org/10.1158/0008-5472.CAN-06-1500
55. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007; 67:10804-12; PMID:18006825; http://dx.doi.org/10.1158/0008-5472.CAN-07-2310
56. Mitchell RA, Chang BF, Huang CH, DeMaster EG. Inhibition of mitochondrial energy-linked functions by arsenate. Evidence for a nonhydrolytic mode of inhibitor action. Biochemistry 1971; 10:2049-54; PMID: 4327397; http://dx.doi.org/10.1021/bi00787a013
57. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62:3893-903; PMID:12124315
58. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126:107-20; PMID:16839880; http://dx.doi.org/10.1016/j.cell.2006.05.036
59. Bensaad K, Cheung EC, Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J 2009; 28:3015-26; PMID:19713938; http://dx.doi.org/10.1038/emboj.2009.242
60. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006; 13:689-706; PMID:16954425; http://dx.doi.org/10.1677/erc.1.00846
61. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004; 22:1605-13; PMID:15117982; http://dx.doi.org/10.1200/JCO.2004.02.112
62. Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011; 117:6425-37; PMID:21422471; http://dx.doi.org/10.1182/blood-2010-11-283598
63. Pontiggia O, Rodriguez V, Fabris V, Raffo D, Bumaschny V, Fiszman G, et al. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions. Breast Cancer Res Treat 2009; 116:247-55; PMID:18622696; http://dx.doi.org/10.1007/s10549-008- 0113-3
64. Samudio I, Fiegl M, McQueen T, Clise-Dwyer K, Andreeff M. The warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008; 68:5198-205; PMID:18593920; http://dx.doi.org/10.1158/0008-5472.CAN-08-0555
65. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 2004; 64:1331-7; PMID:14973050; http://dx.doi.org/10.1158/0008-5472.CAN-03-1860
66. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 2009; 4:e7965; PMID:19956757; http://dx.doi.org/10.1371/journal.pone.0007965
67. Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 2010; 53:2086-8; PMID:20645073; http://dx.doi.org/10.1007/s00125-010-1855-0
68. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33:1674-85; PMID:20587728; http://dx.doi.org/10.2337/dc10-0666
69. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33:1304-8; PMID:20299480; http://dx.doi.org/10.2337/dc09-1791
70. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620-5; PMID:19564453; http://dx.doi.org/10.2337/dc08-2175
71. Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011; 20:101-11; PMID:21119073; http://dx.doi.org/10.1158/1055-9965.EPI-10-0817
72. Jiralerspong S, Palla SL, Giordano SH,Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297-302; PMID:19487376; http://dx.doi.org/10.1200/JCO.2009.19.6410
73. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 3:1077-83.
74. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) 3:1060-5.
75. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147:386-99; PMID:17638715
76. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and metaanalysis. BMJ 2003; 327:951-3; PMID:14576245; http://dx.doi.org/10.1136/bmj.327.7421.951
77. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101:5328-35; PMID:15044693; http://dx.doi.org/10.1073/pnas.0400053101
78. Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009; 27:504-10; PMID:19075265; http://dx.doi.org/10.1200/JCO.2008.18.6130
79. Harris LN, Broadwater G, Abu-Khalaf M, Cowan D, Thor AD, Budman D, et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J Clin Oncol 2009; 27:3430-6; PMID:19470942; http://dx.doi.org/10.1200/JCO.2008.18.4085
80. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15:68-74; PMID:19122658; http://dx.doi.org/10. 1038/nm.1908
81. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-26; PMID:15591335; http://dx.doi.org/10.1056/ NEJMoa041588
82. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, et al. Caveolin-1-/-null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol 2009; 174:746-61; PMID:19234134; http://dx.doi.org/10.2353/ajpath.2009.080658
83. Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, et al. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J Pathol 2009; 174:613-29; PMID:19164602; http://dx.doi.org/10.2353/ajpath.2009.080653
84. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9:3534-51; PMID:20864819; http://dx.doi.org/10.4161/cc.9.17.12908